PA5-18522

antibody from Invitrogen Antibodies

Targeting: LEPR CD295, OBR

Western blot

Immunohistochemistry

Flow cytometry

Antibody data

Submit

Validation data

Product number: PA5-18522 - Provider product page
Provider: Invitrogen Antibodies
Product name: Leptin Receptor Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: This antibody is predicted to react with canine based on sequence homology. This antibody is tested in Peptide ELISA: antibody detection limit dilution 128,000.
Reactivity: Human, Mouse, Rat
Host: Goat
Isotype: IgG
Vial size: 100 µg
Concentration: 0.5 mg/mL
Storage: -20° C, Avoid Freeze/Thaw Cycles

LEPR protein structure - PA5-18522 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 Immunofluorescence staining of defect areas at 6 weeks after surgery. ( A ) Representative images of immunofluorescence staining of CGRP and LepR. ( B ) Representative images of CGRP and Emcn staining. ( C ) Representative images of CGRP and CD31 staining. ( D ) Quantification of CGRP, LepR, Emcn and CD31 median fluorescence intensity (MFI) per field view. Nuclei were stained with DAPI (blue). Scale bar: 100 mum. Data represent means +- standard deviations (n = 6). For all charts, groups labeled with different lowercase letters are significantly different (p < 0.05). Fig. 4

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 7 Sensory nerve-derived Sema3A promotes osteogenesis and angiogenesis in SCS-mediated bone regeneration. ( A ) Micro-CT analysis of bone regeneration at 12 weeks. 3D reconstructed superficial and interior images of femoral condyle defects in different groups. Scale bar: 4 cm. ( B ) Quantitative analysis of bone volume/total volume (TV/BV), bone mineral density (BMD) and Trabecular Thickness (Tb.Th) (n = 6). ( C ) Representative images of immunofluorescence staining of Leptin Receptor and CGRP. ( D ) Representative images of immunofluorescence staining of CGRP and Emcn. ( E ) Representative images of immunofluorescence staining of CGRP and CD31. ( F ) Quantification of CGRP, LepR, Emcn and CD31 median fluorescence intensity (MFI) per field view. Nuclei were stained with DAPI (blue). Scale bar: 100 mum. For all charts, data represent means +- standard deviations (n = 6). Groups labeled with different lowercase letters are significantly different (p < 0.05). Fig. 7

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 EREG regulated glucose uptake via binding with LepR in Lep ob mice. ( A ) EREG and insulin tolerance test in Lep ob mice ( n = 5 per group) treated with a single intraperitoneal injection of insulin (0.012 IU/g BW, triangle dashed line) or EREG (80 ng/g BW, closed circles. Asterisks, significant (* p < 0.05) compared to glucose levels before EREG treatment. # Hashtag, significant difference in glucose levels 30 min after treatment with EREG or insulin. Unpaired Student's t -test. ( B ) Area under the curve (AUC) quantification of insulin (hatched bar) and EREG (black bar) tolerance tests. Unpaired Student's t -test, ns . ( C ) GTT kinetics were measured in Lep ob mice ( n = 5 per treatment) treated with a single injection of PBS (Veh, open circles) or EREG (closed circles). Student's t -test. * p < 0.05 from comparison between control and EREG treated mice at each time point. ( D ) Area under the curve (AUC) quantification of insulin (hatched bar) and EREG (black bar) tolerance tests. Unpaired Student's t -test. ( E , F ). Immunoprecipitation of LepR was performed with anti-EREG antibody using homogenates from subcutaneous fat ( C ) and visceral fat ( D ). Fat tissue was isolated from non-treated Lep ob (Veh) as well as Lep ob mice 15 min after injection of EREG (50 ng/mL).